Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study
- PMID: 37154966
- DOI: 10.1007/s00203-023-03574-0
Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study
Abstract
Chronic inflammation and immune activation are a hallmark of HIV-1 infection. In this study, we assessed inflammation biomarkers in a cohort of people living with HIV-1 (PLWH) before and after long-term suppressive combined antiretroviral therapy (cART). A single-center prospective cohort study was conducted to assess inflammatory biomarkers in 86 cART-naive PLWH and after receiving suppressive cART and 50 uninfected controls. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and soluble CD14 (sCD14) were measured using enzyme-linked immunosorbent assay (ELISA). No significant difference was found in IL-6 levels between cART-naïve PLWH and controls (p = 0.753). In contrast, TNF-α level showed a significant difference between cART naïve-PLWH and controls (p = 0.019). Interestingly, IL-6 and TNF-α levels were significantly decreased in PLWH after cART (p < 0.0001). The sCD14 showed no significant difference between cART-naïve patients and controls (p = 0.839) and similar levels were observed in pre- and post-treatment (p = 0.719). Our results highlight the critical importance of early treatment to reduce inflammation and its consequences during HIV infection.
Keywords: AIDS; Antiretroviral therapy; HIV; IL-6; TNF-α; sCD14.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
TNF-α levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects.J Antimicrob Chemother. 2014 Nov;69(11):3041-6. doi: 10.1093/jac/dku263. Epub 2014 Jul 9. J Antimicrob Chemother. 2014. PMID: 25011654
-
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.BMC Infect Dis. 2014 Mar 4;14:122. doi: 10.1186/1471-2334-14-122. BMC Infect Dis. 2014. PMID: 24589015 Free PMC article.
-
Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.BMC Cardiovasc Disord. 2022 Sep 3;22(1):393. doi: 10.1186/s12872-022-02835-y. BMC Cardiovasc Disord. 2022. PMID: 36057773 Free PMC article.
-
Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.HIV Med. 2015 Oct;16(9):553-62. doi: 10.1111/hiv.12257. Epub 2015 May 6. HIV Med. 2015. PMID: 25944318
-
Asymptomatic HIV People Present Different Profiles of sCD14, sRAGE, DNA Damage, and Vitamins, according to the Use of cART and CD4+ T Cell Restoration.J Immunol Res. 2018 Apr 10;2018:7531718. doi: 10.1155/2018/7531718. eCollection 2018. J Immunol Res. 2018. PMID: 29992171 Free PMC article.
References
-
- Baker JV, Neuhaus J, Duprez D et al (2011) Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 56:36–43. https://doi.org/10.1097/QAI.0b013e3181f7f61a - DOI - PubMed - PMC
-
- Baker JV, Sharma S, Grund B et al (2017) Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis 21:770. https://doi.org/10.1186/s13063-020-04678-4 - DOI
-
- Beignon A-S (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor- viral RNA interactions. J Clin Investig 115:3265–3275. https://doi.org/10.1172/JCI26032 - DOI - PubMed - PMC
-
- Borges ÁH, Silverberg MJ, Wentworth D et al (2013) Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 27:1433–1441. https://doi.org/10.1097/QAD.0b013e32835f6b0c - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials